rs12086634 — HSD11B1 Intron 3 variant

Modulates local cortisol activation from cortisone in liver and adipose tissue, influencing visceral fat, insulin sensitivity, and metabolic syndrome risk

See your personal result for HSD11B1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

HSD11B1 Intron 3 — The Tissue Cortisol Switch

Your adrenal glands release cortisone, an inactive form of cortisol, into the bloodstream. Inside tissues — particularly liver, adipose tissue, and brain — the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1, encoded by HSD11B1) converts cortisone back into active cortisol11 cortisol
the primary stress glucocorticoid, with wide effects on glucose, fat, and immune function. This local amplification means that intracellular cortisol concentrations in fat and liver can substantially exceed plasma levels — a separate, tissue-controlled glucocorticoid environment. The rs12086634 variant sits in an enhancer element in intron 322 enhancer element in intron 3
a non-coding regulatory region that boosts transcription of the nearby gene of HSD11B1 and modulates how much enzyme is produced. Because the G allele reduces transcription in vitro, carriers produce less 11beta-HSD1 and regenerate less cortisol locally, while the common T allele (especially TT homozygotes combined with the rs846910 A allele) is linked to higher enzyme expression and activity.

The Mechanism

The intron 3 enhancer region of HSD11B1 responds to tissue-specific transcription factors. In vitro reporter assays show that the G allele reduces transcriptional activity33 reduces transcriptional activity
Draper et al. J Clin Endocrinol Metab 2006 compared to the common T allele. Less enzyme means less cortisone-to-cortisol conversion in adipose tissue and liver. The downstream consequences run in two directions: (1) lower local glucocorticoid activity may reduce visceral fat deposition and insulin resistance risk — hence the G allele's protective signal in some populations; (2) the corresponding higher cortisol clearance (more cortisol excreted as cortisone) triggers the HPA axis to compensate, increasing ACTH-driven adrenal output and paradoxically raising adrenal androgen production in susceptible individuals.

The enzyme relies on NADPH provided by hexose-6-phosphate dehydrogenase (H6PD)44 NADPH provided by hexose-6-phosphate dehydrogenase (H6PD)
H6PD acts as the luminal NADPH generator; mutations in H6PD cause cortisone reductase deficiency in the endoplasmic reticulum lumen. Reduced HSD11B1 expression shifts the enzyme's net directionality away from cortisol regeneration toward cortisone formation.

The Evidence

A study of 102 Caucasian PCOS patients vs 98 controls55 102 Caucasian PCOS patients vs 98 controls
Draper et al. J Clin Endocrinol Metab 2006 found the G allele associated with PCOS status (P = 0.041), driven entirely by lean patients (P = 0.025). G allele carriers had lower morning plasma cortisol and higher ACTH-stimulated cortisol response66 lower morning plasma cortisol and higher ACTH-stimulated cortisol response
suggesting enhanced cortisol clearance with compensatory HPA activation, elevated DHEA-S, and — notably — lower LDL cholesterol, consistent with reduced glucocorticoid activity in the liver. These findings suggest the G allele may confer metabolic protection while simultaneously predisposing lean women to adrenal hyperandrogenism.

A larger study of 600 women with and without PCOS77 600 women with and without PCOS
Gambineri et al. Eur J Endocrinol 2011 found that the TT genotype at rs12086634 combined with the rs846910 A allele (GA/TT haplotype) was associated with metabolic syndrome at OR 2.77 (95% CI 1.16–6.67), P = 0.02388 OR 2.77 (95% CI 1.16–6.67), P = 0.023, regardless of PCOS diagnosis. Women with this haplotype had higher HSD11B1 mRNA in adipose tissue and a significantly elevated cortisol regeneration rate (16.1 ± 0.7 vs 12.1 ± 1.1 nmol/min, P = 0.044). This positions the T allele (not G) as the risk allele for metabolic syndrome in the context of the combined haplotype.

In 616 South Indian subjects99 616 South Indian subjects
Velmurugan et al. Endocr Connect 2017, the TG genotype (one G copy) contributed to increased risk of both type 2 diabetes (OR 1.91; 95% CI 1.33–2.76, P = 0.0005) and metabolic syndrome (OR 2.37; 95% CI 1.39–4.05, P = 0.0015), and was associated with elevated systolic blood pressure compared to TT controls. This contrasts with some European studies and underscores the population-dependent complexity of these associations.

A systematic review1010 systematic review
Torchen et al. Int J Diabetes Dev Ctries 2015 concluded that HSD11B1 variants play only a small role in most populations, with stronger associations in Indian and Pima Indian cohorts, and largely null findings in East Asian and French-Canadian populations.

Separately, HSD11B1 polymorphisms in intron 51111 HSD11B1 polymorphisms in intron 5
Stavrou et al. Osteoporos Int 2009 were significantly associated with femoral neck bone mineral density (P = 0.00005) and vertebral fracture risk in 1,329 postmenopausal women, consistent with the known role of local glucocorticoid excess in suppressing osteoblast activity and promoting adipogenic differentiation of bone marrow progenitor cells.

Practical Implications

For people carrying the G allele (GT or GG), the likely effect is modestly reduced 11beta-HSD1 activity — meaning less local cortisol regeneration in fat and liver. This may offer metabolic protection (lower visceral fat accumulation tendency) but at the cost of higher HPA axis activity. For TT homozygotes, particularly those who also carry the rs846910 A allele, the evidence points toward elevated tissue cortisol regeneration, which manifests as higher metabolic syndrome risk, elevated fasting glucose, and in women, a tendency toward visceral fat accumulation.

Monitoring fasting glucose and waist circumference is particularly relevant for TT homozygotes. Compounds that reduce 11beta-HSD1 activity — including liquorice-derived carbenoxolone1212 liquorice-derived carbenoxolone
a non-selective 11beta-HSD inhibitor studied in clinical trials, and dietary patterns that lower cortisol burden — have been explored as strategies but are not yet clinically actionable for this specific variant. Selective 11beta-HSD1 inhibitors remain in pharmaceutical development.

For bone health, the broader HSD11B1 data on fracture risk and BMD suggests that individuals with high local glucocorticoid activity (likely TT carriers with elevated enzyme expression) should prioritize bone density monitoring as they age.

Interactions

The functionally important interaction is with rs846910 in the HSD11B1 promoter region. The Gambineri 2011 study demonstrates that the combined GA (rs846910) + TT (rs12086634) haplotype is the high-activity combination: together they elevate HSD11B1 mRNA expression and cortisol regeneration rate in adipose tissue, with OR 2.77 for metabolic syndrome. Single-SNP analyses of either variant alone show weaker effects. This is a classic gene-gene interaction within the same gene — the two regulatory variants appear to act additively on transcriptional output.

Compound interaction proposal: Individuals carrying rs846910 GA genotype AND rs12086634 TT genotype both have an approximately 2.8-fold elevated metabolic syndrome risk and higher adipose cortisol regeneration. The combined recommendation for this haplotype: monitor fasting glucose, insulin, and waist circumference annually, and consider time-restricted eating patterns that minimize cortisol-mediated postprandial insulin surges. Both individual variant recommendations are subsumed by this combined finding.

Genotype Interpretations

What each possible genotype means for this variant.

GT Intermediate Cortisol Activator Intermediate

One G allele modestly reduces local cortisol regeneration; elevated metabolic risk seen in some populations

The GT genotype creates a mixed regulatory state: one allele with lower transcriptional activity (G) and one with higher (T). The net effect on 11beta-HSD1 expression lies between GG and TT. The South Indian association data for TG (OR ~1.91–2.37) is notable and may reflect that even heterozygous reduction of enzyme activity creates metabolic imbalance in the context of high-carbohydrate dietary patterns or other genetic modifiers common in that population.

The finding that TG genotype shows higher systolic blood pressure than TT in South Indian controls is intriguing and may reflect a different direction of effect — perhaps the G allele in this population acts differently due to LD with other nearby variants not captured by this SNP alone.

GG Low Cortisol Activator Decreased

Two copies of the G allele substantially reduce local cortisol regeneration from cortisone

The GG genotype represents the homozygous reduced-enzyme state. The reduced HSD11B1 expression shifts the tissue glucocorticoid balance away from cortisol, potentially protecting against the metabolic syndrome phenotype seen in high-enzyme-expression individuals. The trade-off is increased compensatory HPA activity — the hypothalamus and pituitary perceive lower tissue cortisol feedback and upregulate ACTH accordingly. This is evident in the Draper 2006 study showing G allele carriers have lower morning plasma cortisol but a more robust cortisol response to ACTH stimulation, and elevated DHEA-S reflecting higher adrenal androgenic output.

In the context of bone health, lower local cortisol regeneration in osteoblasts may be protective against glucocorticoid-induced bone loss, though direct GG-specific bone data are limited.

TT High Cortisol Activator High

Two T alleles support higher HSD11B1 expression, increasing local cortisol regeneration and metabolic syndrome risk

The TT genotype sustains high transcriptional activity of HSD11B1 via the intron 3 enhancer. This means adipocytes and hepatocytes convert more cortisone to cortisol, bathing these tissues in higher glucocorticoid concentrations than plasma measurements reveal. This intracellular cortisol excess directly: (1) promotes preadipocyte differentiation into mature adipocytes, preferentially in visceral depots; (2) drives gluconeogenesis in the liver, raising fasting glucose; (3) antagonizes insulin signalling at the insulin receptor and GLUT4 translocation level.

The Gambineri 2011 study demonstrated that TT/GA haplotype carriers had measurably higher cortisol appearance rates during steady-state d3-cortisol infusion — direct kinetic evidence of greater enzymatic cortisol regeneration. This is not merely an association study; it is mechanistic confirmation in humans.

For bone: HSD11B1 is expressed in osteoblasts, and local cortisol excess suppresses osteoblast proliferation and function while promoting adipogenic differentiation of mesenchymal progenitors. Studies of linked HSD11B1 intron 5 variants show significant BMD associations (p = 0.00005 at femoral neck) and reduced vertebral fracture risk in 1,329 postmenopausal women.